Revenue rose to $24.2M in Q3 2026 with gross margins steady between 74% and 78%, though operating margin of 33.6% and EPS of $0.51 were pressured by a sharp growth slowdown in Q2 2026 to 0.3% year-over-year.
IRadimed Corporation (IRMD) annual income statement — 14-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 89.34M | 83.81M | 73.24M | 65.56M | 53.3M | 41.81M | 31.72M | 38.52M | 30.44M | 23.08M | 32.5M | 31.59M | 15.65M | 11.34M | 7.69M |
| Revenue Growth % | 10.97% | 14.43% | 11.71% | 23% | 27.47% | 31.83% | -17.65% | 26.54% | 31.88% | -28.97% | 2.86% | 101.84% | 38.03% | 47.56% | - |
| Cost of Goods Sold | 21.88M | 19.49M | 16.89M | 15.4M | 12.02M | 9.76M | 8.14M | 8.82M | 7.21M | 5.57M | 6.15M | 5.84M | 3.4M | 2.85M | 2.13M |
| COGS % of Revenue | - | 23.25% | 23.06% | 23.5% | 22.55% | 23.35% | 25.67% | 22.89% | 23.69% | 24.13% | 18.94% | 18.49% | 21.75% | 25.16% | 27.66% |
| Gross Profit | 67.46M | 64.32M | 56.35M | 50.16M | 41.28M | 32.05M | 23.57M | 29.7M | 23.23M | 17.51M | 26.34M | 25.75M | 12.25M | 8.49M | 5.56M |
| Gross Margin % | 75.51% | 76.75% | 76.94% | 76.5% | 77.45% | 76.65% | 74.33% | 77.11% | 76.31% | 75.87% | 81.06% | 81.51% | 78.25% | 74.84% | 72.34% |
| Gross Profit Growth % | - | 14.15% | 12.34% | 21.5% | 28.81% | 35.95% | -20.63% | 27.87% | 32.64% | -33.52% | 2.28% | 110.25% | 44.33% | 52.66% | - |
| Operating Expenses | 38.6M | 38.18M | 34.39M | 30.12M | 25.65M | 22.23M | 24.33M | 21.05M | 17.22M | 16.23M | 15.42M | 14.24M | 9.18M | 5.7M | 4.13M |
| OpEx % of Revenue | - | 45.55% | 46.95% | 45.95% | 48.13% | 53.17% | 76.71% | 54.66% | 56.58% | 70.3% | 47.46% | 45.07% | 58.66% | 50.26% | 53.8% |
| Selling, General & Admin | 35.31M | 35.2M | 31.55M | 27.26M | 23.38M | 20.33M | 22.43M | 19.62M | 15.71M | 14.5M | 14.07M | 12.48M | 8.11M | 4.69M | 3.48M |
| SG&A % of Revenue | - | 42% | 43.08% | 41.59% | 43.86% | 48.61% | 70.71% | 50.94% | 51.6% | 62.84% | 43.31% | 39.49% | 51.84% | 41.35% | 45.29% |
| Research & Development | 3.29M | 2.98M | 2.83M | 2.86M | 2.28M | 1.91M | 1.9M | 1.43M | 1.52M | 1.72M | 1.35M | 1.76M | 1.07M | 1.01M | 654.07K |
| R&D % of Revenue | - | 3.55% | 3.87% | 4.36% | 4.27% | 4.56% | 6% | 3.72% | 4.98% | 7.46% | 4.15% | 5.58% | 6.83% | 8.91% | 8.51% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Operating Income | 28.86M | 26.15M | 21.96M | 20.04M | 15.63M | 9.82M | -756.09K | 8.65M | 6M | 1.29M | 10.92M | 11.51M | 3.07M | 2.79M | 1.42M |
| Operating Margin % | 32.3% | 31.2% | 29.99% | 30.56% | 29.32% | 23.48% | -2.38% | 22.45% | 19.72% | 5.57% | 33.6% | 36.44% | 19.59% | 24.58% | 18.54% |
| Operating Income Growth % | - | 19.04% | 9.63% | 28.21% | 59.18% | 1398.48% | -108.74% | 44.03% | 367.22% | -88.23% | -5.15% | 275.52% | 10% | 95.64% | - |
| EBITDA | 30.64M | 27.31M | 22.78M | 20.8M | 16.3M | 11.22M | 582.73K | 9.89M | 7.11M | 2.59M | 11.17M | 11.74M | 3.21M | 2.93M | 1.53M |
| EBITDA Margin % | 34.29% | 32.59% | 31.11% | 31.73% | 30.58% | 26.84% | 1.84% | 25.68% | 23.35% | 11.24% | 34.37% | 37.15% | 20.54% | 25.8% | 19.92% |
| EBITDA Growth % | 18.59% | 19.89% | 9.53% | 27.62% | 45.2% | 1826.18% | -94.11% | 39.12% | 174.07% | -76.78% | -4.85% | 265.08% | 9.87% | 91.14% | - |
| D&A (Non-Cash Add-back) | 1.25M | 1.17M | 817.66K | 765.18K | 670.67K | 1.41M | 1.34M | 1.24M | 1.11M | 1.31M | 248.3K | 223.94K | 149.06K | 139.04K | 106.28K |
| EBIT | 30.62M | 28.36M | 24.28M | 21.74M | 16.18M | 9.84M | -756.09K | 8.65M | 6.2M | 1.4M | 10.95M | 11.63M | 3.02M | 2.78M | 1.43M |
| Net Interest Income | 0 | 0 | 2.19M | 1.86M | 581.85K | 34.81K | 132.19K | 388.8K | 238.11K | 122.58K | 126.42K | 148.91K | 5.7K | 0 | 0 |
| Interest Income | 0 | 0 | 2.19M | 1.86M | 581.85K | 34.81K | 132.19K | 388.8K | 238.11K | 122.58K | 126.42K | 148.91K | 5.7K | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 2.25M | 2.21M | 2.31M | 1.7M | 553.1K | 18.61K | 139.21K | 395.91K | 193.54K | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Pretax Income | 31.12M | 28.36M | 24.28M | 21.74M | 16.18M | 9.84M | -616.88K | 9.04M | 6.2M | 1.4M | 10.95M | 11.63M | 3.02M | 2.78M | 1.43M |
| Pretax Margin % | 34.83% | 33.84% | 33.14% | 33.16% | 30.36% | 23.52% | -1.94% | 23.48% | 20.36% | 6.05% | 33.7% | 36.83% | 19.28% | 24.55% | 18.63% |
| Income Tax | 7.13M | 5.88M | 5.04M | 4.55M | 3.35M | 510.82K | -1.99M | -587.64K | -106.14K | 896.62K | 3.74M | 4.1M | 966.98K | 846.88K | 465.98K |
| Effective Tax Rate % | 22.92% | 20.74% | 20.77% | 20.91% | 20.72% | 5.19% | 321.92% | -6.5% | -1.71% | 64.21% | 34.13% | 35.28% | 32.05% | 30.42% | 32.54% |
| Net Income | 23.98M | 22.48M | 19.23M | 17.19M | 12.83M | 9.33M | 1.37M | 9.63M | 6.3M | 499.76K | 7.21M | 7.53M | 2.05M | 1.94M | 966.09K |
| Net Margin % | 26.85% | 26.82% | 26.26% | 26.22% | 24.07% | 22.3% | 4.32% | 25% | 20.71% | 2.17% | 22.2% | 23.83% | 13.1% | 17.08% | 12.57% |
| Net Income Growth % | 13.21% | 16.88% | 11.87% | 34.02% | 37.56% | 581.19% | -85.79% | 52.79% | 1161.29% | -93.07% | -4.19% | 267.25% | 5.86% | 100.49% | - |
| Net Income (Continuing) | 23.98M | 22.48M | 19.23M | 17.19M | 12.83M | 9.33M | 1.37M | 9.63M | 6.3M | 499.76K | 7.21M | 7.53M | 2.05M | 1.94M | 966.09K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.86 | 1.75 | 1.50 | 1.35 | 1.02 | 0.74 | 0.11 | 0.78 | 0.52 | 0.04 | 0.60 | 0.60 | 0.20 | 0.19 | 0.09 |
| EPS Growth % | 13.33% | 16.67% | 11.11% | 32.35% | 37.84% | 572.73% | -85.9% | 50% | 1200% | -93.33% | 0% | 200% | 5.26% | 104.74% | - |
| EPS (Basic) | - | 1.77 | 1.52 | 1.36 | 1.02 | 0.76 | 0.11 | 0.85 | 0.52 | 0.05 | 0.67 | 0.68 | 0.23 | 0.19 | 0.09 |
| Diluted Shares Outstanding | 12.88M | 12.85M | 12.78M | 12.72M | 12.64M | 12.59M | 12.44M | 12.28M | 12.11M | 11.72M | 11.99M | 12.56M | 10.22M | 10.42M | 10.42M |
| Basic Shares Outstanding | 12.79M | 12.72M | 12.67M | 12.6M | 12.56M | 12.35M | 12.12M | 11.28M | 12.11M | 10.64M | 10.82M | 11M | 8.74M | 10.42M | 10.42M |
| Dividend Payout Ratio | - | 66.9% | 71.11% | 76.91% | 97.9% | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying IRMD stock.
For fiscal year 2025, IRadimed Corporation (IRMD) reported total revenue of $83.8M. This represents a 990.6% increase compared to $7.7M in 2012.
IRadimed Corporation (IRMD) is profitable, generating $22.5M in net income for the fiscal year ending 2025 with a net profit margin of 26.8%.
IRadimed Corporation (IRMD) reported an operating income of $26.1M, resulting in an operating profit margin of 31.2%. This margin reflects the operational efficiency of the business before interest and taxes.
IRadimed Corporation (IRMD) generated $64.3M in gross profit for the year, representing a gross profit margin of 76.7%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Q2 EPS miss
Metrics are mathematically derived from official filings.
Revenue Growth Steady but Decelerating
Based on the reported quarterly figures, IRMD's revenue grew from $17.9M in Q2 2024 to $24.2M in Q3 2026, though year-over-year growth swung sharply, falling to just 0.3% in Q2 2026 before recovering to 14.2% in Q3.
The reported figures suggest a business whose top line is compounding at a healthy mid-teens pace over the longer horizon, yet the Q2 2026 near-stall indicates quarterly growth remains lumpy. This pattern is consistent with large multi-unit hospital orders and distributor timing rather than a smooth recurring-revenue run rate, so investors should monitor whether the Q3 rebound persists. Durability of growth will depend on whether disposable consumption scales with MRI procedure volumes as hardware placements fluctuate.
Gross Margin Structurally Anchored near 75%
Reported gross margins have held in a narrow band of roughly 74% to 78% across the ten quarters, with Q2 2026 at 74.1% and Q3 2026 at 76.3%, consistent with a specialized, high-pricing-power device niche.
A stable gross margin of this magnitude suggests IRMD's proprietary non-magnetic pump architecture supports pricing that is largely insulated from commodity cost swings. The modest compression toward 74% in Q2 2026 may reflect product mix or early launch costs for the 3870 platform, but the data do not isolate the cause. Sustained margins near 76% would indicate the pricing moat is intact, while a persistent drift lower would warrant closer scrutiny of cost inputs.
Operating Leverage Visible but Uneven
Operating margin expanded from 31.6% in Q3 2024 to 33.6% in Q3 2026, though it dipped to 31.2% in Q2 2026, suggesting incremental revenue converts to operating income only partially each quarter.
Operating income of $8.1M on $24.2M revenue in Q3 2026 indicates that opex growth has been broadly contained relative to gross profit growth. However, SG&A stepped up to $9.4M in Q3 2026 against $7.8M in Q3 2024, which suggests overhead is growing alongside revenue rather than diluting from it. Investors should monitor whether the operating margin can hold above 32% as the 3870 launch scales.
Net Margin Tracks Operations Closely
Net margin of 26.9% in Q3 2026 sits near operating margin of 33.6%, and reported diluted EPS of $0.51 versus $0.41 in Q2 2026 indicates net income is moving in line with operating results rather than being driven by non-operating items.
The gap between operating and net margin appears consistent across periods, which suggests a stable tax and non-operating profile rather than one-off gains flattering results. Stock-based compensation of roughly $0.7M to $0.8M per quarter is modest relative to net income, limiting its distortion of reported earnings. The Q2 2026 EPS shortfall versus consensus, however, is best understood as an operating miss rather than an accounting artifact.
Fixed R&D and SG&A Base Carries the Model
R&D spending of $875K in Q3 2026 and SG&A of $9.4M against $24.2M revenue show that overhead, not direct cost of goods, is the dominant cost burden, with COGS of $5.7M representing about 24% of revenue.
The cost profile implies a high fixed-cost base in regulatory, sales, and administrative functions that scales efficiently only if revenue keeps rising. R&D has fluctuated between roughly $570K and $956K per quarter, which may reflect timing of 3870 development milestones rather than a structural shift in investment intensity. Management's expense discipline appears adequate, though the data do not disclose headcount or program-level detail needed to fully judge it.
Q2 2026 Marks the Earnings Pressure Point
Q2 2026 represents the clearest inflection in the reported history, with revenue falling to $20.5M from $22.0M in Q1 and EPS dropping to $0.41, the lowest in the recent run before a rebound to $0.51 in Q3.
The Q2 2026 decline coincides with the launch period for the next-generation pump, and the reported figures suggest early launch costs or unfavorable mix may have been the proximate drivers, though the filings provided do not confirm this attribution. The rapid Q3 recovery to $24.2M revenue and $0.51 EPS suggests the disruption was transitory rather than structural. Investors should watch whether the recovery is sustained as the new platform matures.
Growth Quality and Margin Sustainability Questioned
Bears would point to the volatile quarterly growth path, including the 0.3% revenue growth in Q2 2026 and the 8.9% EPS decline year over year, as evidence that the recurring-revenue narrative may be overstated relative to hardware timing.
A skeptical reading suggests that the high margins depend on continued placement of hardware and sustained disposable utilization, both of which may be sensitive to hospital capital budgets and procedure volumes that the data do not fully reveal. The maintained forward guidance implies a sharp sequential rebound that warrants scrutiny, since failure to deliver could further pressure the valuation. Investors should monitor whether margins hold near 75% and whether the 3870 transition proves smoother than the Q2 2026 results indicate.